Yuekang M. Li

No. 79, Qingchun Road
Hangzhou, 310003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Cytokine fusion proteins for solid tumor therapy: mechanistic insights and clinical advances.

Cytokine fusion proteins for solid tumor therapy: mechanistic insights and clinical advances.

Journal: Journal of hematology & oncology

Published: May 25, 2026

Clinical outcomes of concomitant anti-PD-1 therapy and denosumab treatment in non-small cell lung cancer patients with bone metastasis: a single-center retrospective study.

Clinical outcomes of concomitant anti-PD-1 therapy and denosumab treatment in non-small cell lung cancer patients with bone metastasis: a single-center retrospective study.

Journal: Discover oncology

Published: January 29, 2026

Neutrophil extracellular traps induce airway epithelial-mesenchymal transition in a neutrophil-dominant asthmatic murine model through Hedgehog/Gli1 pathway.

Neutrophil extracellular traps induce airway epithelial-mesenchymal transition in a neutrophil-dominant asthmatic murine model through Hedgehog/Gli1 pathway.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: August 19, 2025

Immune profiling identifies CD161+CD127+CD8+ T cells as a predictive biomarker for Anti-PD-L1 therapy response in the SCLC-I subtype.

Immune profiling identifies CD161+CD127+CD8+ T cells as a predictive biomarker for Anti-PD-L1 therapy response in the SCLC-I subtype.

Journal: Journal of translational medicine

Published: February 18, 2025

IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in PDAC.

IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in PDAC.

Journal: Cell reports

Published: January 08, 2025

Identifying risk factors and biomarkers for severe CIP in lung cancer patients- a retrospective case series study.

Identifying risk factors and biomarkers for severe CIP in lung cancer patients- a retrospective case series study.

Journal: Immunotherapy

Published: November 26, 2024

Immunotherapy rechallenge after ICI-related pneumonitis in lung cancer patients: a retrospective cohort study.

Immunotherapy rechallenge after ICI-related pneumonitis in lung cancer patients: a retrospective cohort study.

Journal: Frontiers in oncology

Published: November 13, 2024

CD161+CD127+CD8+ T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus.

CD161+CD127+CD8+ T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus.

Journal: Oncoimmunology

Published: July 02, 2024

Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer.

Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 05, 2023

Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.

Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.

Journal: Signal transduction and targeted therapy

Published: January 05, 2023

Deubiquitinating enzymes: Promising targets for drug resistance.

Deubiquitinating enzymes: Promising targets for drug resistance.

Journal: Drug discovery today

Published: February 03, 2022

Machado-Joseph Deubiquitinases: From Cellular Functions to Potential Therapy Targets.

Machado-Joseph Deubiquitinases: From Cellular Functions to Potential Therapy Targets.

Journal: Frontiers in pharmacology

Published: April 22, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026